Changes in microbiome in oral cavity, nasal cavity, oro- or nasopharynx · Healthcare workers (HCWs) treating patients with suspected or confirmed COVID-19 infection
The review found no eligible studies for this question.
1 finding from 1 review
Incidence of symptomatic or test-positive COVID-19 infection in HCWs · Healthcare workers (HCWs) treating patients with suspected or confirmed COVID-19 infection
The review found no eligible studies for this question.
1 finding from 1 review
Other adverse events (allergy, irritation/burning of nasal, oral or oropharyngeal mucosa, long-term staining of mucous membranes or teeth, accidental ingestion) · Healthcare workers (HCWs) treating patients with suspected or confirmed COVID-19 infection
The review found no eligible studies for this question.
1 finding from 1 review
Marginal bone level change · Patients affected by chronic, aggressive, or early onset periodontitis, with intrabony defects having an intrabony component of at least 3…
1 finding from 1 review
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether intralesional triamcinolone changes maximal mouth opening (interincisal distance) compared with intralesional triamcinolone plus salvianolic acid B (very low certainty).
1 finding from 1 review
Burning sensation (VAS 0-100) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether intralesional triamcinolone changes burning sensation (VAS 0-100) compared with intralesional triamcinolone plus salvianolic acid B (very low certainty).
2 findings from 1 review
MD -1.00 [-10.37, 8.37]
1 study · 28 participants
Very low
MD -16.30 [-28.15, -4.45]
1 study · 28 participants
Very low
Clinical resolution · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Intralesional betamethasone may leads to higher clinical resolution compared with intralesional triamcinolone acetonide (low certainty).
1 finding from 1 review
Clinical score (14 days) · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
It is very uncertain whether intralesional betamethasone changes clinical score (14 days) compared with intralesional triamcinolone acetonide (very low certainty).
1 finding from 1 review
Pain (mean score) · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Intralesional betamethasone showed no clear difference in pain (mean score) compared with intralesional triamcinolone acetonide (low certainty).
1 finding from 1 review
Presence of dry socket · Adults (>18 years) having permanent tooth extraction (predominantly mandibular third molars)
Tranexamic acid (AMCA cones) showed no clear difference in presence of dry socket compared with placebo (lactose cones); GRADE not reported.
1 finding from 1 review
Pain / clinical response (not analysable) · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
1 finding from 1 review
Secondary outcome: Dermatology Quality of Life measure · People with erosive oral lichen planus
1 finding from 1 review
Pain reduction (VAS 0-100) · People with erosive oral lichen planus
1 finding from 1 review
In the Hegarty 2002 cross-over trial (n=22), no statistical testing of the pain score (VAS 0 to 100) was reported; it is not clear whether the difference is statistically significant (fluticasone mean score 19.8 versus…
1 study · 22 participants
GRADE not reported
Reduction in target/mean lesion size · People with erosive oral lichen planus
1 finding from 1 review
Side effects · People with erosive oral lichen planus
1 finding from 1 review
Table 3 (Side-effects). Hegarty 2002: nausea (4), swollen mouth (1), bad taste and smell (6), difficulty in spray application (7), dry mouth (2), sore throat (1), red painful tongue (1), and pseudomembranous…
1 study · 44 participants
GRADE not reported
Clinical score · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
It is very uncertain whether systemic (oral) betamethasone changes clinical score compared with topical triamcinolone acetonide paste (very low certainty).
1 finding from 1 review
Pain resolution · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
It is very uncertain whether systemic (oral) betamethasone changes pain resolution compared with topical triamcinolone acetonide paste (very low certainty).
1 finding from 1 review
Clinical response (not analysable) · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
1 finding from 1 review
Side effects · People with erosive oral lichen planus
1 finding from 1 review
Table 3 (Side-effects). Malhotra 2008: betamethasone oral mini-pulse - transient oedema over the face (7), oedema over hands and feet (4), epigastric discomfort (7), weakness/fatigue (5), loose stools (1), headache…
1 study · 22 participants
GRADE not reported
Investigator‐ or physician‐rated global assessment of disease severity · People with erosive oral lichen planus
Betamethasone oral mini-pulse therapy led to higher physician Global Assessment (clinical severity, 0-12 score) compared with topical triamcinolone acetonide 0.1% paste; GRADE not reported.
1 finding from 1 review